Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)

Rhea-AI Summary

Panbela Therapeutics, Inc. (Nasdaq: PBLA) announces that an abstract for SBP-101, a proprietary polyamine analogue, will be presented at the American Association for Cancer Research (AACR) meeting from April 8-13, 2022. This research highlights a collaboration with Johns Hopkins University. SBP-101 aims to inhibit polyamine metabolism, showing promising results in clinical studies for metastatic pancreatic cancer, including a median overall survival of 12 months and an objective response rate of 48%. The safety profile indicates no exacerbation of common chemotherapy-related side effects.

Positive

• SBP-101 demonstrates promising clinical results with a median overall survival of 12 months in metastatic pancreatic cancer patients.
• Objective response rate (ORR) of 48%, surpassing standard chemotherapy treatment outcomes.
• No exacerbation of bone marrow suppression or peripheral neuropathy, common chemotherapy side effects, observed in patients.

Negative

• None.

MINNEAPOLIS, March 07, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR), which will be held April 8-13, 2022. The work reflects the Company’s on-going collaboration with Johns Hopkins University School of Medicine.

Details of the presentation are as follows:

Poster Presentation

• Title: The potential of spermine analogue SBP-101 (diethyl dihydroxyhomospermine) as a polyamine metabolism modulator in ovarian cancer
  
  
• Session Category: Experimental and Molecular Therapeutics
  Session Title: Small Molecule Therapeutic Agents Abstract #: 5488 

• Additional meeting information can be found on the AACR website: Abstracts | AACR Annual Meeting 2022 | April 8-13, 2022 | New Orleans
  
  
• The abstract and poster will also be available on the Company's website at https://panbela.com/events-presentations/ once the information has been released by AACR
  
  

About SBP-101

SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, demonstrating a median overall survival (OS) of 12.0 months which is not yet final, and an objective response rate (ORR) of 48%, both exceeding what is seen typically with the standard of care of gemcitabine + nab-paclitaxel suggesting potential complementary activity with the existing FDA-approved standard chemotherapy regimen. In data evaluated from clinical studies to date, SBP-101 has not shown exacerbation of bone marrow suppression and peripheral neuropathy, which can be chemotherapy-related adverse events. Serious visual adverse events have been evaluated and patients with a history of retinopathy or at risk of retinal detachment will be excluded from future SBP-101 studies. The safety data and PMI profile observed in the current Panbela sponsored clinical trial provides support for continued evaluation of SBP-101 in a randomized clinical trial. For more information, please visit https://clinicaltrials.gov/ct2/show/NCT03412799 .

About Panbela

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company’s initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. is dedicated to treating patients with pancreatic cancer, ovarian cancer, and exploring SBP-101’s potential for efficacy in combination with other agents in other cancer indications. Further information can be found at www.panbela.com. Panbela Therapeutics, Inc. common stock is listed on The Nasdaq Stock Market LLC under the symbol PBLA.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements,” including within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “believe,” “expect,” “feel,” “intend,” “may,” “plan,” and “scheduled.” Examples of forward-looking statements include statements we make regarding our intention to continue to innovate and build our patent portfolio. All statements other than statements of historical fact are statements that should be deemed forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially and adversely from the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) our ability and the combined company’s ability to obtain additional funding to complete clinical trials; (ii) progress and success of our Phase 1 clinical trial; (iii) the impact of the current COVID-19 pandemic on our ability to complete monitoring and reporting in our current clinical trial and procure the active ingredient; (iv) our ability to demonstrate the safety and effectiveness of our SBP-101 product candidate (v) our ability to obtain regulatory approvals for our SBP-101 product candidate in the United States, the European Union or other international markets; (vi) the market acceptance and level of future sales of our SBP-101 product candidate; (vii) the cost and delays in product development that may result from changes in regulatory oversight applicable to our SBP-101 product candidate; (viii) the rate of progress in establishing reimbursement arrangements with third-party payors; (ix) the effect of competing technological and market developments; (x) the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims; and (xi) such other factors as discussed in Part I, Item 1A under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, any additional risks presented in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Any forward-looking statement made by us in this press release is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement or reasons why actual results would differ from those anticipated in any such forward-looking statement, whether written or oral, whether as a result of new information, future developments or otherwise.

Contact Information:

Investors: 
James Carbonara 
Hayden IR 
(646) 755-7412 
james@haydenir.com

Media: 
Tammy Groene 
Panbela Therapeutics, Inc. 
(952) 479-1196 
IR@panbela.com

FAQ

What is the significance of SBP-101 in pancreatic cancer treatment?

SBP-101 shows promising results, including a median overall survival of 12 months and a 48% objective response rate in metastatic pancreatic cancer, suggesting it may complement existing chemotherapy.

When will the SBP-101 data be presented?

The data on SBP-101 will be presented at the American Association for Cancer Research (AACR) meeting from April 8-13, 2022.

What collaboration is Panbela Therapeutics involved in for SBP-101?

Panbela Therapeutics is collaborating with Johns Hopkins University School of Medicine on the development of SBP-101.

What type of cancer is SBP-101 targeting?

SBP-101 is targeting metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer.

What are the future prospects for SBP-101 based on current studies?

The current studies support further evaluation of SBP-101 in randomized clinical trials due to its favorable safety profile and efficacy signals.